Malignant Gliomas as Second Neoplasms in Pediatric Cancer Survivors: Neuropathological Study

Table 1

Clinical details of the patients.

	P1	P2	P3	P4	P5
Primary cancer	ALL low risk	ALL low risk	ALL high risk	ALL high risk	RMS right maxillary sinus
Age at primary; cancer diagnosis	9,5 years	6,8 years	2,8 years	4 years	11 years
CNS infiltration; at primary tumor	No	No	Yes/recurrence	Yes/at diagnosis	No
Brain RTX; (total dose)	Prophylactic (12 Gy)	Prophylactic (12 Gy)	Therapeutic (24 Gy)	Therapeutic (24 Gy)	No CNS radiotherapy
Response to therapy of primary tumor	CR	CR	CR	CR	CR
	3 years	3,5 years	6,5 years	5 years	2 years
Age at brain tumor diagnosis	15,5 years	12,3 years	12 years	12 years	15 years
Brain tumor	Glioblastoma	Glioblastoma	Glioblastoma	Anaplastic astrocytoma	Glioblastoma
Localization	Right frontoparietal	Left frontoparietal	Left temporoparietooccipital	Right frontoparietotemporal	Left temporal
SMG therapy	Biopsy, tumor resection, CHT, RTX	Tumor biopsy, CHT	Partial tumor resection, CHT	Tumor biopsy, CHT	Biopsy, repeated biopsy, tumor resection, CHT, RTX; after 6 yr 2nd tumorectomy, CHT
Outcome	Death of PD; 19 mth	Death of PD; 5 mth	Death of PD; 10 mth	Death of PD; 9 mth	Death of PD; 12 years

Abbreviations. ALL: acute lymphoblastic leukemia, RMS: rhabdomyosarcoma, CNS: central nervous system, RTX: radiotherapy, CR: complete remission, : period between the end of the first malignancy treatment and brain tumor diagnosis, SMG: secondary malignant glioma, CHT: chemotherapy, PD: progression of disease.